These questions assessed from laboratory scientists, physicians, and patient organization, how satisfied they are with manufacturers policies on introducing new RIs as well as whether there was a risk-benefit analysis measures in place when switching from immunoassays to mass spectrometry methods.
5._collection_of_outreach_for_comments.pdf